All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Efficacy and safety of JNJ-77242113 in patients with moderate-to-severe psoriasis: Long-term extension FRONTIER-2 trial
|
In the phase IIb FRONTIER-1 trial (NCT05223868), JNJ-77242113, an oral IL-23 inhibitor, improved response rates vs placebo at Week 16 in patients with moderate-to-severe plaque psoriasis.1 The FRONTIER-2 trial (NCT05364554) assessed the safety and efficacy of JNJ-77242113 through to Week 52 in 227 patients who completed FRONTIER-1.1 Results from this trial were published in the Journal of the American Academy of Dermatology by Ferris et al.1 |
| Key learnings |
| At Week 52, 49%, 58%, 70%, 65%, 76%, and 66% of patients achieved a PASI 75 response in 25 mg QD, 25 mg BID, 50 mg QD, 100 mg QD, 100 mg BID, and placebo→100 mg QD groups, respectively. |
| The proportion of patients achieving PASI 90, PASI 100, IGA 0/1, and IGA 0 responses at Week 16 were generally maintained through Week 52, with the highest response rates in the higher dose groups. |
| Improvements in PRO measures at Week 16 were maintained through Week 52, and no new safety signals were observed. |
| Results from this trial demonstrate that the improvements in clinical and PRO measures with JNJ-77242113 at Week 16 were durable through Week 52 with no new safety signals, and patients switching from placebo to JNJ-77242113 100 mg QD experienced rapid improvements in response rates. Abbreviations: MDA, minimal disease activity; PsA, psoriatic arthritis. |
Abbreviations: BID, twice daily; IGA, Investigator’s Global Assessment; IL, interleukin; LTE, long-term extension; PASI, Psoriasis Area and Severity Index; PRO, patient-reported outcomes; QD, once daily.
- Ferris LK, Bagel H, Huang YH, et al. FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. Online ahead of print. DOI: 10.1016/j.jaad.2024.10.076
More about...
Your opinion matters
10 votes - 50 days left ...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox